van der Laken C J, Boerman O C, Oyen W J, van de Ven M T, van der Meer J W, Corstens F H
Department of Nuclear Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands.
Eur J Nucl Med. 1998 May;25(5):535-46. doi: 10.1007/s002590050255.
Various conventional radiopharmaceuticals are currently available for scintigraphic imaging of infection and inflammation. Although a wide variety of infectious and inflammatory foci can be detected with these agents, several disadvantages limit their application. These limitations have stimulated the search for new radiopharmaceuticals. In the past decade a new class of radiopharmaceuticals has emerged: radiolabelled receptor-specific small proteins and peptides. These proteins and peptides are naturally occurring inflammatory mediators which specifically bind to receptors abundantly present in the area of inflammation. In addition, owing to their small size, they rapidly clear from all non-target tissues. This paper provides an overview of these newly developed agents, focussing on imaging characteristics and in vivo uptake mechanisms.
目前有多种传统放射性药物可用于感染和炎症的闪烁成像。尽管使用这些药物可以检测到各种各样的感染性和炎症病灶,但一些缺点限制了它们的应用。这些局限性促使人们寻找新的放射性药物。在过去十年中,一类新的放射性药物出现了:放射性标记的受体特异性小蛋白和肽。这些蛋白和肽是天然存在的炎症介质,它们特异性地结合在炎症区域大量存在的受体上。此外,由于它们的体积小,它们能迅速从所有非靶组织中清除。本文概述了这些新开发的药物,重点介绍其成像特征和体内摄取机制。